Tetrahydrokanabiorkol (THCR / THC-C1) · Sales discontinued in CZ
THCR, full name tetrahydrocannabiorcol (sometimes also THC-C1), is a very rare minor phytocannabinoid with only a single-carbon side chain. It belongs to the same family of varins and THC homologs as THCV, THCB and THCP.
THCR is a psychoactive cannabinoid falling into the same regulatory group as THCP and THCB. Distribution and sale of THCR for human consumption have been prohibited in the CZ since 2025 by the amendment to Act No. 167/1998 Coll. Tato stránka slouží pouze jako informační zdroj a v naší nabídce THCR aktuálně nenajdete.
THCR is a natural cannabinoid that occurs in cannabis only in trace amounts (usually below 0.01%). Structurally it is the shortest known THC homolog – its alkyl side chain consists of just a single carbon (hence the THC-C1 designation, where 'C1' refers to methyl). For comparison: THCV has three carbons, THC five, THCP seven. This extremely short chain length strongly affects binding to the CB1 receptor, significantly weakening it – THCR's affinity for CB1 is therefore substantially lower than that of THC. Commercially THCR appeared exclusively as a semi-synthetic product made from CBD or CBG, because extraction from natural cannabis is economically unfeasible.
In Europe THCR briefly passed through the market in 2023–2024 mainly in the form of enriched flowers, vape pen cartridges and combined 'blends' with HHCP or THCP, where it served more as a marketing bonus than as the main active substance. After the regulatory wave that hit semi-synthetic THC derivatives, THCR was practically withdrawn from the legal market and buyers today look for it mainly for informational reasons. The vast majority of available user experiences thus comes from a very small sample of people and any controlled clinical data is missing.
THCR effects are described as mildly psychoactive, significantly weaker than classical THC. Users most often report light euphoria, gentle relaxation and short duration of effect (1.5–3 hours after inhalation). Some people describe an almost imperceptible effect – this is consistent with in-vitro data suggesting low THCR affinity for CB1. Side effects correspond to the typical THC homolog profile: dry mouth, red eyes, mild tachycardia and short-term impairment of concentration. Given the laboratory origin of most commercial products, the presence of residual precursors and solvents from production was also a significant risk. No clinical THCR studies in humans have been published to date.
In the Czech Republic THCR is, as of 2025, listed among prohibited psychoactive cannabinoids. It falls under the same amendment to Act No. 167/1998 Coll. that restricted HHC, HHCP, THCP and other semi-synthetic derivatives. Distribution, sale and possession for the purpose of distribution constitute the offense of unauthorized production and other handling of narcotic and psychotropic substances. THCR has the same status in most EU countries. We recommend consulting the current state with a lawyer specialized in criminal law or with the State Institute for Drug Control. CBDsvět.cz does not and will not sell THCR – for daily wellbeing we offer legal full-spectrum CBD oils, CBG or CBN.
Legislation is evolving. This text is not legal advice – for specific cases we recommend consulting a lawyer.
| Cannabinoid | Potency | Duration | Legality CZ |
|---|---|---|---|
| THCR (THC-C1) | Slabě psychoaktivní | 1,5–3 h | CZ – banned |
| THCV (C3) | Mírně psychoaktivní | 1,5–3 h | CZ – legal |
| Δ9-THC (C5) | Plně psychoaktivní | 2–4 h | CZ – addictive substance |
| THCP (C7) | Až 33× CB1 afinita THC | 6–8 h | CZ – banned |
| CBD | Nepsychoaktivní | 4–6 h | Legal in EU |
THCR cannot currently be legally purchased in the Czech Republic. These products are fully legal and support the endocannabinoid system.
THCR is tetrahydrocannabiorcol – a THC analog with only a single-carbon (methyl) side chain. The 'C1' designation refers to the length of this chain.
You might also be interested in